We previously reported that novel targeted "hybrid
peptide" in which
epidermal growth factor receptor (EGFR) binding
peptide was conjugated with lytic-type
peptide had selective cytotoxic activity to EGFR expressing
cancer cell lines, and in vivo analysis revealed that this
EGFR-lytic peptide displayed significant antitumor activity in a xenograft model of human
breast cancer which was resistant to
tyrosine kinase inhibitor drugs. As an attempt to improve the selective anticancer activity of
EGFR-lytic peptide, we modified the EGFR-binding
peptide through introducing the mutation of
amino acid according to biophysical analysis by biomolecular interaction and circular dichroism (CD) spectra. When cytotoxic activity of EGFR-lytic or EGFR(2R)-lytic hybrid
peptides was investigated in various human
cancer and normal cell lines, it was demonstrated that EGFR(2R)-lytic, in which second
histidine (H) of EGFR-binding
peptide was replaced to
arginine (R) had 1.2-1.9-fold higher cytotoxic activity than that of original
EGFR-lytic peptide. In vivo analysis also revealed that this modified
peptide displayed significant antitumor activity at as low as 1 mg/kg dosage. These results suggest that mutated
arginine on
EGFR-lytic peptide produces higher binding ability to EGFR on
cancer cells, and thereby the improved anticancer activity.